Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621

References

• Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276:60 - 6; http://dx.doi.org/10.1126/science.276.5309.60; PMID: 9082986
   PubMed Web of Science ®Google Scholar
• Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6:1997 - 2003; PMID: 1719465
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915 - 25; http://dx.doi.org/10.1038/nrm1261; PMID: 14685170
   PubMed Web of Science ®Google Scholar
• Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376:768 - 71; http://dx.doi.org/10.1038/376768a0; PMID: 7651534
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373:699 - 702; http://dx.doi.org/10.1038/373699a0; PMID: 7854452
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 2012; 12:89-103; PMID: 22270953; DOI: 10.1038/nrc3205; 10.1038/nrc3205.
   Google Scholar
• Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13:41 - 59; http://dx.doi.org/10.1016/S1359-6101(01)00029-6; PMID: 11750879
   PubMed Web of Science ®Google Scholar
• Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15:49 - 51; http://dx.doi.org/10.1038/sj.cr.7290264; PMID: 15686627
   PubMed Web of Science ®Google Scholar
• Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87:1063 - 9; http://dx.doi.org/10.1111/j.1349-7006.1996.tb03111.x; PMID: 8957065
   PubMedGoogle Scholar
• Han SU, Lee JH, Kim WH, Cho YK, Kim MW. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 1999; 23:1176 - 80; http://dx.doi.org/10.1007/s002689900642; PMID: 10501881
   PubMed Web of Science ®Google Scholar
• Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60:6737 - 43; PMID: 11118060
   PubMed Web of Science ®Google Scholar
• Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001; 61:7518 - 24; PMID: 11606388
   PubMed Web of Science ®Google Scholar
• Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, et al. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003; 24:1317 - 23; http://dx.doi.org/10.1093/carcin/bgg072; PMID: 12807719
   PubMed Web of Science ®Google Scholar
• Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225:1 - 26; http://dx.doi.org/10.1016/j.canlet.2004.09.044; PMID: 15922853
   PubMed Web of Science ®Google Scholar
• Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001; 98:7443 - 8; http://dx.doi.org/10.1073/pnas.131200498; PMID: 11416216
   PubMed Web of Science ®Google Scholar
• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7:504 - 16; http://dx.doi.org/10.1038/nrd2530; PMID: 18511928
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408 - 17; http://dx.doi.org/10.1158/0008-5472.CAN-06-4443; PMID: 17483355
   PubMed Web of Science ®Google Scholar
• Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010; 10:556; http://dx.doi.org/10.1186/1471-2407-10-556; PMID: 20946682
   PubMed Web of Science ®Google Scholar
• Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005; 11:2312 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-04-1708; PMID: 15788682
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960; PMID: 18519697
   PubMed Web of Science ®Google Scholar
• Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-05-1418; PMID: 17062691
   PubMed Web of Science ®Google Scholar
• van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, et al. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia 2009; 11:355 - 64; PMID: 19308290
   PubMed Web of Science ®Google Scholar
• Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008; 7:1913 - 22; http://dx.doi.org/10.1158/1535-7163.MCT-07-2169; PMID: 18645002
   PubMed Web of Science ®Google Scholar
• Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009; 8:3181 - 90; http://dx.doi.org/10.1158/1535-7163.MCT-09-0477; PMID: 19934279
   PubMed Web of Science ®Google Scholar
• Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 2008; 49:129 - 34; http://dx.doi.org/10.2967/jnumed.106.038836; PMID: 18077531
   PubMed Web of Science ®Google Scholar
• Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231:11 - 23; http://dx.doi.org/10.1016/S0022-1759(99)00137-4; PMID: 10648924
   PubMed Web of Science ®Google Scholar
• Graziani A, Gramaglia D, Cantley LC, Comoglio PM. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 1991; 266:22087 - 90; PMID: 1718989
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11:834 - 48; http://dx.doi.org/10.1038/nrm3012; PMID: 21102609
   PubMed Web of Science ®Google Scholar
• Jeffers M, Rong S, Anver M, Vande Woude GF. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene 1996; 13:853 - 6; PMID: 8761307
   PubMed Web of Science ®Google Scholar
• Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12:5152 - 8; PMID: 1406687
   PubMed Web of Science ®Google Scholar
• Rong S, Oskarsson M, Faletto D, Tsarfaty I, Resau JH, Nakamura T, et al. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 1993; 4:563 - 9; PMID: 8398896
   PubMedGoogle Scholar
• Tajima H, Matsumoto K, Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 1992; 202:423 - 31; http://dx.doi.org/10.1016/0014-4827(92)90095-P; PMID: 1327854
   PubMed Web of Science ®Google Scholar
• Okano Y, Mizuno K, Osada S, Nakamura T, Nozawa Y. Tyrosine phosphorylation of phospholipase C gamma in c-met/HGF receptor-stimulated hepatocytes: comparison with HepG2 hepatocarcinoma cells. Biochem Biophys Res Commun 1993; 190:842 - 8; http://dx.doi.org/10.1006/bbrc.1993.1125; PMID: 7679901
   PubMed Web of Science ®Google Scholar
• Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, Bioulac-Sage P, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997; 26:1458 - 66; http://dx.doi.org/10.1002/hep.510260612; PMID: 9397985
   PubMed Web of Science ®Google Scholar
• Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A 2006; 103:4046 - 51; http://dx.doi.org/10.1073/pnas.0509040103; PMID: 16537482
   PubMed Web of Science ®Google Scholar
• Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, et al. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc Natl Acad Sci U S A 2007; 104:14592 - 7; http://dx.doi.org/10.1073/pnas.0704290104; PMID: 17804794
   PubMed Web of Science ®Google Scholar
• Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu HE. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci U S A 2010; 107:13264 - 9; http://dx.doi.org/10.1073/pnas.1005183107; PMID: 20624990
   PubMed Web of Science ®Google Scholar
• Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, et al. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000; 6:327 - 31; http://dx.doi.org/10.1038/73187; PMID: 10700236
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343 - 57; http://dx.doi.org/10.1038/nri1837; PMID: 16622479
   PubMed Web of Science ®Google Scholar
• Tangri S, Mothé BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 2005; 174:3187 - 96; PMID: 15749848
   PubMed Web of Science ®Google Scholar
• Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999; 91:1548 - 56; http://dx.doi.org/10.1093/jnci/91.18.1548; PMID: 10491431
   PubMed Web of Science ®Google Scholar
• Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006; 103:2316 - 21; http://dx.doi.org/10.1073/pnas.0508776103; PMID: 16461907
   PubMed Web of Science ®Google Scholar
• Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006; 103:5090 - 5; http://dx.doi.org/10.1073/pnas.0508156103; PMID: 16547140
   PubMed Web of Science ®Google Scholar
• Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97:1841 - 8; http://dx.doi.org/10.1002/cncr.11335; PMID: 12673709
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM, Wurch T. 5th european antibody congress 2009: November 30-december 2, 2009, geneva, switzerland. MAbs 2010; 2:108 - 28; http://dx.doi.org/10.4161/mabs.2.2.11302; PMID: 20179425
   PubMedGoogle Scholar
• Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, et al. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One 2012; 7:e34658; http://dx.doi.org/10.1371/journal.pone.0034658; PMID: 22511956
   PubMedGoogle Scholar
• Goetsch L. Antibodies inhibiting c-met dimerization, and therapeutic (anticancer) and diagnostic uses thereof. PCT Int Appl 2009; 2008-EP59026; 2007-301231:175.
   Google Scholar
• Goetsch L, Wurch T, Bes C. Anti-c-met antibodies for cancer therapy. PCT Int Appl 2011; 2011-EP59139; 2010-791681:119.
   Google Scholar
• Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998; 111:237 - 47; PMID: 9405310
   PubMed Web of Science ®Google Scholar
• Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004; 6:75 - 84; http://dx.doi.org/10.1016/j.ccr.2004.06.013; PMID: 15261143
   PubMed Web of Science ®Google Scholar
• Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010; 285:36149 - 57; http://dx.doi.org/10.1074/jbc.M110.134031; PMID: 20833723
   PubMed Web of Science ®Google Scholar
• Sharma N, Adjei AA. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol 2011; 3:Suppl S37 - 50; http://dx.doi.org/10.1177/1758834011423403; PMID: 22128287
   PubMedGoogle Scholar
• Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11:1655 - 62; http://dx.doi.org/10.1517/14712598.2011.626762; PMID: 22047509
   PubMed Web of Science ®Google Scholar
• Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther 2012; 12:519 - 28; http://dx.doi.org/10.1586/era.12.16; PMID: 22500688
   PubMed Web of Science ®Google Scholar
• Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011; 1:573 - 9; http://dx.doi.org/10.1158/2159-8290.CD-11-0175; PMID: 22389872
   PubMed Web of Science ®Google Scholar
• Schwall RH, Adams CW, Zheng Z, Romero M, Mai E, Moffat B, et al. Inhibition of cMet activation by a one-armed antibody. AACR Meeting Abstracts 2004; 2004:327-b-.
   Google Scholar
• Reyes AE II, Xiang H, Bender B, Haughney P, Oldendorp A, Nijem I, et al. Pharmacokinetics of a novel one-armed antibody to C-met in mice, rats, and monkeys. AAPS PharmSci 2008; 10:S2 587
   Google Scholar
• Institute of Laboratory Animal Resources (U.S.). Guide for the Care and use of Laboratory Animals. Washington, D.C.; Great Britain: National Academy Press, 1996.
   Google Scholar